Petal Surgical

Based in the US, Petal Surgical is a medical technology company specializing in innovative surgical procedures using their proprietary Acoustic Liquefaction technology to enhance surgical outcomes while minimizing complications. Petal Surgical, founded in 2021 and headquartered in Redwood City, US, focuses on developing advanced surgical solutions through its proprietary technology. The company has successfully completed 1 deal to date, with its most recent funding round being a Series A on October 20, 2025, during which it raised USD 10. 00 mn from investors including K50 Ventures, TSVC, Draper, and ShangBay Capital.

The founder's detailed history is currently unavailable. Petal Acoustic Liquefaction Surgery specializes in innovative surgical solutions centered around their proprietary technology known as Acoustic Liquefaction. This platform utilizes focused acoustic energy to precisely manipulate targeted tissue without the need for incisions, heat, or trauma. The main goal of this technology is to enable the body’s natural healing processes while minimizing surgical complications, which are a significant concern within the medical community.

Their process involves focused high-intensity sound waves that create a predictable vapor cavity, liquefying diseased cells while leaving surrounding healthy tissues intact. The end users of these services primarily include hospitals and surgical centers, particularly those specializing in minimally invasive procedures. Geographically, Petal targets markets in North America, Europe, and parts of Asia, aiming to enhance surgical outcomes and access to safe surgical care globally. Petal Acoustic Liquefaction Surgery operates under a business model that emphasizes partnerships with healthcare facilities and surgical centers, positioning itself as a provider of advanced surgical technology.

Revenue generation occurs primarily through direct sales of their Acoustic Liquefaction system to hospitals, complemented by ongoing service agreements and training for clinical staff on its use. The structure of transactions typically involves upfront capital investment from healthcare facilities to acquire the technology, along with potential recurring fees for maintenance and updates. This model allows Petal to secure a steady revenue stream while ensuring that healthcare providers are equipped to utilize their innovative solution effectively. Specific pricing details for the system and associated services are proprietary and are determined based on the individual agreements with healthcare providers.

In October 2025, Petal Surgical raised USD 10. 00 mn in Series A funding, co-led by K50 Ventures and TSVC, with participation from Draper and ShangBay Capital. The company plans to utilize these funds to accelerate the development of new products aimed at enhancing surgical capabilities, with specific release dates pending. Additionally, Petal intends to expand its presence in new markets, targeting regions in Asia and Europe by 2026, to broaden access to their innovative surgical solutions.